Predict your next investment

Corporation
HEALTHCARE | Medical Devices & Equipment / Imaging & Diagnostic Equipment
rundamedical.com

See what CB Insights has to offer

Founded Year

1999

Stage

IPO | IPO

About Shanghai Runda Medical Technology

Shanghai Runda Medical Technology (603108.SH) is an integrated service provider of medical laboratory services. The company's core business is providing a range of in vitro diagnostics (IVD) products and professional technical support for medical laboratories.

Shanghai Runda Medical Technology Headquarter Location

Room D-I, 15/F,Orient International Science & Technology Mansion 58 Xiangcheng Rd., Pudong District

Shanghai, Shanghai, 200122,

China

021-50817880

Latest Shanghai Runda Medical Technology News

Response Biomedical Corp. Completes Going-Private Transaction

Nov 29, 2016

VANCOUVER, BRITISH COLUMBIA--(Marketwired - Nov. 29, 2016) - Response Biomedical Corp. ("Response" or the "Company") (TSX:RBM)(OTC:RPBIF) is pleased to announce that the previously announced acquisition of all the issued and outstanding common shares of Response ("Response Shares") by 1077801 B.C. Ltd., a company beneficially owned by OrbiMed Asia Partners, L.P., OrbiMed Private Investments III, LP, OrbiMed Associates III, LP, OrbiMed Advisors LLC, OrbiMed Advisors Limited, Samuel D. Isaly, and Shanghai Runda Medical Technology Co., Ltd. by way of a plan of arrangement (the "Arrangement") has been completed. Pursuant to the Arrangement, Response shareholders will receive, subject to the terms and conditions of the Arrangement, $1.12 per Response Share (except in the case of certain shareholders who have agreed to roll over their Response Shares and will instead receive shares of 1077801 B.C. Ltd.) and Response will become a wholly-owned subsidiary of 1077801 B.C. Ltd. The Arrangement was approved by the Supreme Court of British Columbia in its final order dated September 19, 2016. The Arrangement remains subject to final approval by the Toronto Stock Exchange (the "TSX"). The delisting of the Response Shares from the TSX is expected to occur at the close of business on or about December 2, 2016. Additional information regarding the terms of the Arrangement is set out in Response's management information circular dated August 11, 2016, which is available under Response's profile at www.sedar.com . About Response Biomedical Corp. Response develops, manufactures and markets rapid on-site diagnostic tests for use with its RAMP® platform for clinical, biodefense and environmental applications. RAMP® represents a unique paradigm in diagnostics that provides reliable, quality results in minutes. The RAMP® platform consists of a reader and single-use disposable test cartridges and has the potential to be adapted to any other medical and non-medical immunoassay based test currently performed in laboratories. Response clinical tests are commercially available for the aid in early detection of heart attack, congestive heart failure, thromboembolism, sepsis, influenza A and B and RSV. In the non-clinical market, RAMP® tests are currently available for the environmental detection of West Nile Virus and Dengue Fever antigen and for Biodefense applications including the rapid on-site detection of anthrax, smallpox, ricin and botulinum toxin. Response is a publicly traded company listed on the TSX under the trading symbol "RBM" and quoted on the OTC under the symbol "RPBIF". For further information, please visit the Company's website at www.responsebio.com . Forward-Looking Statements This press release may contain forward-looking statements, for example statements regarding the approval of the Arrangement by the TSX and the anticipated delisting of the Response Shares. These statements relate to future events and are subject to risks, uncertainties and assumptions about the Company. These statements are only predictions based on the Company's current expectations and projections about future events. Although the Company believes the expectations reflected in such forward-looking statements, and the assumptions upon which such forward-looking statements are made, are reasonable, there can be no assurance that such expectations will prove to be correct and if such expectations are not met, the Company's business may suffer. Readers should not place undue reliance on these statements. Actual events or results may differ materially. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the Company's actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. Among those factors which could cause the Company's actual results to differ materially from any forward-looking statements are the following: market conditions and other risk factors listed from time to time detailed in our filings with the Securities and Exchange Commission and Canadian securities regulatory authorities, including but not limited to our Annual Report on Form 10-K, our Quarterly Reports on Form 10-Q, our Current Reports on Form 8-K and other filings with the Securities and Exchange Commission and Canadian securities regulatory authorities. The forward-looking statements included in this press release are made as of the date of this press release and the Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by applicable securities legislation. Contact Information

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Shanghai Runda Medical Technology Patents

Shanghai Runda Medical Technology has filed 4 patents.

The 3 most popular patent topics include:

  • Conditions of the mucous membranes
  • Dental equipment
  • Dentistry
patents chart

Application Date

Grant Date

Title

Related Topics

Status

4/30/2018

10/8/2019

Dentistry, Conditions of the mucous membranes, Oral mucosal pathology, Dental equipment, Salivary gland pathology

Grant

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

Application Date

4/30/2018

00/00/0000

00/00/0000

00/00/0000

Grant Date

10/8/2019

00/00/0000

00/00/0000

00/00/0000

Title

Subscribe to see more

Subscribe to see more

Subscribe to see more

Related Topics

Dentistry, Conditions of the mucous membranes, Oral mucosal pathology, Dental equipment, Salivary gland pathology

Subscribe to see more

Subscribe to see more

Subscribe to see more

Status

Grant

Subscribe to see more

Subscribe to see more

Subscribe to see more

Shanghai Runda Medical Technology Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Shanghai Runda Medical Technology Rank

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.